Market Overview

UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Related NBIX
US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data
UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation

Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target.

Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments of unmet need. We believe the Street undervalues this asset. We expect elagolix success in endometriosis and uterine fibroids (UF) and model combined WW sales of ~$720mn in 2020."

Neurocrine Biosciences closed at $8.30 on Wednesday.

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (NBIX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free